276 P.H. Reggio
Griffin G, Wray EJ, Rorrer WK, Crocker PJ, Ryan WJ, Saha B, Razdan RK, Martin BR, Abood
ME (1999) An investigation into the structural determinants of cannabinoid receptor
ligand efficacy. Br J Pharmacol 126:1575–1584
Griffin G, Tao Q, Abood ME (2000) Cloning and pharmacological characterization of the
rat CB(2) cannabinoid receptor. J Pharmacol Exp Ther 292:886–894
Guarnieri F, Weinstein H (1996) Conformational memories and the exploration of biolog-
ically relevant peptide conformations: an illustration for the gonadotropin-releasing
hormone. J Am Chem Soc 118:5580–5589
HanusL,BreuerA,TchilibonS,ShiloahS,GoldenbergD,HorowitzM,PertweeRG,Ross
RA, Mechoulam R, Fride E (1999) HU-308: a specific agonist for CB(2), a peripheral
cannabinoid receptor. Proc Natl Acad Sci U S A 96:14228–14233
HanusL,Abu-LafiS,FrideE,BreuerA,VogelZ,ShalevDE,KustanovichI,Mechoulam
R (2001) 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1
receptor. Proc Natl Acad Sci U S A 98:3662–3665
HillardCJ,MannaS,GreenbergMJ,DiCamelliR,RossRA,StevensonLA,MurphyV,Pertwee
RG, Campbell WB (1999) Synthesis and characterization of potent and selective agonists
of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther 289:1427–1433
Howlett AC, Johnson MR, Melvin LS, Milne GM (1988) Nonclassical cannabinoid analgetics
inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol Pharmacol
33:297–302
Huffman JW, Dai D, Martin BR, Compton DR (1994) Design, synthesis and pharmacology
of cannabimimetic indoles. Bioorg Med Chem Lett 4:563–566
Huffman JW, Yu S, Showalter V, Abood ME, Wiley JL, Compton DR, Martin BR, Bramblett
RD, Reggio PH (1996) Synthesis and pharmacology of a very potent cannabinoid lacking
a phenolic hydroxyl with high affinity for the CB2 receptor. J Med Chem 39:3875–3877
Huffman JW, Yu S, Liddle J, Wiley JL, Abood M, Martin BR, Aung MM (1998) 1998 Sym-
posium on the Cannabinoids; International Cannabinoid Research Society; Burlington,
VT. 10 [ISBN: 09658053-2-096580538]
Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, Wiley JL, Martin BR (1999) 3-(1′,1′-
Dimethylbutyl)-1-deoxy-delta-8-THC and related compounds: synthesis of selective
ligands for the CB2 receptor. Bioorg Med Chem 7:2905–2914
Huffman JW, Bushell SM, Miller JR, Wiley JL, Martin BR (2002) 1-Methoxy-, 1-deoxy-
11-hydroxy- and 11-hydroxy-1-methoxy-delta-8-tetrahydrocannabinols: new selective
ligands for the CB(2) receptor. Bioorg Med Chem 10:4119–4129
HuffmanJW,MabonR,WuMJ,LuJ,HartR,HurstDP,ReggioPH,WileyJL,MartinBR
(2003) 3-Indolyl-1-naphthylmethanes: new cannabimimetic indoles provide evidence
for aromatic stacking interactions with the CB(1) cannabinoid receptor. Bioorg Med
Chem 11:539–549
Hulme EC, Lu ZL, Ward SD, Allman K, Curtis CA (1999) The conformational switch in 7-
transmembrane receptors: the muscarinic receptor paradigm. Eur J Pharmacol 375:247–
260
Hurst DP, Lynch DL, Barnett-Norris J, Hyatt SM, Seltzman HH, Zhong M, Song ZH, Nie
J, Lewis D, Reggio PH (2002) N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichloro-
phenyl)-4-methyl-1H-p yrazole-3-carboxamide (SR141716A) interaction with LYS
3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol Phar-
macol 62:1274–1287
Iwamura H, Suzuki H, Ueda Y, Kaya T, Inaba T (2001) In vitro and in vivo pharmacological
characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J
Pharmacol Exp Ther 296:420–425
Jarai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR, Zimmer AM, Bonner TI,
Buckley NE, Mezey E, Razdan RK, Zimmer A, Kunos G (1999) Cannabinoid-induced
mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.
Proc Natl Acad Sci U S A 96:14136–14141
Jensen AD, Guarnieri F, Rasmussen SG, Asmar F, Ballesteros JA, Gether U (2001) Agonist-
induced conformational changes at the cytoplasmic side of transmembrane segment 6